MRI bei Kardiomyopathien - Unispital Basel · MRI bei Kardiomyopathien KardioUpdate 09.05.2019...

Post on 22-May-2020

12 views 0 download

Transcript of MRI bei Kardiomyopathien - Unispital Basel · MRI bei Kardiomyopathien KardioUpdate 09.05.2019...

MRI bei KardiomyopathienKardioUpdate 09.05.2019

Philip Haaf

Kardiologische Klinik, Universitätsspital Basel

MRI & Cardiomyopathies

1. Definition of Cardiomyopathy

2. Ischemic vs Non-ischemic cardiomyopathy

3. Tissue characterization with MRI for differential diagnosis of the

a.“dilated ventricle”

b.“thick ventricle”

4. Decision making: MRI for arrhythmogenic risk stratification

1. What is a cardiomyopathy?

Myocardial disorder in which the heart muscle is

structurally and/or functionally abnormal,

in the absence of

CAD

hypertension

valvular disease

congenital heart disease

sufficient to explain the observed myocardial abnormality.

McKenna WJ et al. Circ Res 2017

1. What is a cardiomyopathy?

Myocardial disorder in which the heart muscle is

structurally and/or functionally abnormal,

in the absence of

CAD

hypertension

valvular disease

congenital heart disease

sufficient to explain the observed myocardial abnormality.

McKenna WJ et al. Circ Res 2017

LGE

T1, T2, T2*,

ECV MappingFlow

Cine

Perfusion

Elliot P et al. Eur Heart J 2008 ESC Position Statement

What is clinically most important?

Morphologic Classification of Cardiomyopathies

Swoboda PP et al. Eur Cardiol 2017, Elliott P et al.

ESC WG on Myocardial and Pericardial Diseases.

Eur Heart J 2008

MOGES Classification

Morpho-Functional Phenotype

Organ/System Involvement

Genetic Inheritance Pattern

Etiology

Stage

Clinical practice (”99%”)

“Thick ventricle”

Hypertrophic cardiomyopathy (HCM)

Amyloidosis

Athlete’s heart

Anderson-Fabry

(Hypertensive heart disease)

“Dilated ventricle”

Dilated cardiomyopathy [NICM ICM]

Myocarditis (post-myocarditis)

ARVC

Iron overload CMP

Takotsubo-CMP

LV non-compaction

2. ICM NICM: LGE patterns

Non-coronary pattern of LGE Non-ischemic CMP

o subendocardium is typically spared

o often more patchy distribution

o localized in mid-wall and subepicardium

Coronary pattern of LGE Ischaemic CMP

o from subendocardium to epicardium

(ischaemic wave front) with increasing

coronary occlusion time

o matching with coronary distribution

mid-wall

patchy

endocardial

transmural

Ischemic vs. Non-ischemic

Images: University Hospital Basel

4Ch Cine 3Ch Cine

Pati

ent

APa

tien

t B

Images: University Hospital Basel

4Ch Cine 3Ch Cine4Ch LGE 3Ch LGE Conclusion

Ischemic

Non-ischemic

(DCM)

Pati

ent

APa

tien

t B

Ischemic vs. Non-ischemic

DCM – CMR features

• Systolic function↓

• Global LV (and RV), biatrial dilatation

• Mild eccentric hypertrophy or wall thinning

• exclusion of „ischaemic LGE“ / ischaemic heart disease

• Septal mid-wall LGE (25-30%); any LGE worse prognosis

In most cases lack of LGE consider T1 mapping

• No myocardial oedema

• Pleural effusion

Mid-wall

DCM

Consider (bystander) CAD in DCM if…

Marked regional wall motion abnormalities that

correspond with a coronary perfusion territory

Subendocardial or transmural LGE

Perfusion imaging can be difficult to interpret in DCM

thin myocardium

presence of scar

often slow blood flow

mri-blog.com

CMR – Histology

Wagner A et al, Lancet, 2003

CMR

Histology

Base Midventricular Apex

Dilated ventricle with LVEF↓↓ and no LGE excludes ICM (>90%).

LGE: breakthrough technique for CMR

Subendocardial Transmural“Ischaemic wave front”

Ischaemic Cardiomyopathy

Cardiac amyloidosis

Non-Ischaemic Cardiomyopathy

DCM

HCM

Myocarditis, Fabry

…ESC CMR pocket guide 2.0

LGE reference standard of myocardial scar and focal fibrosis.

Diffuse fibrosis may go undetected on LGE imaging.

Eitel I, et al. JACC 2014

LGE

Cardiac sarcoidSystemic Sclerosiss

ARVC

Normal myocardium

predominantly (≈75%)

cardiac myocytes

Interstitium (≈25%):

fibroblast, collagen,

endothelial cells, coronary

arteries

Normal ECV map

(≈ 25% ECV)

Normal LGE Myocardial infarction

increased collagen

synthesis with minimal

or no loss of viable

myocytes

Normal LGEHeterogeneous ECV map

green increased ECV >29%

Histopathology of myocardial fibrosis

Rathod R. et al. Circulation 2015

reversibleirreversible

3. Tissue characterization with MRI for DD of the “dilated ventricle”

Dilated cardiomyopathy [NICM ICM]

Myocarditis (post-myocarditis)

ARVC

Iron overload CMP

Takotsubo-CMP

LV non-compaction

Myocarditis /Non-ischemic myocardial inflammation

Typically inferolateral/inferior LGE

with a mid-wall to subepicardial

enhancement

Atypical cases of myocarditis with

transmural or diffuse LGE

Often concomitant LGE involvement

of the pericardium

Myocardial oedema only in the acute

setting

Images: University Hospital Basel

Fibrosis Oedema

Updated Lake Louise Criteria (“2 out of 2”)

Co

ntra

st-fre

eassessm

en

tfe

asib

le

(T1 a

nd

T2 m

appin

g)

3. Tissue characterization with MRI for DD of the “dilated ventricle”

Dilated cardiomyopathy [NICM ICM]

Myocarditis (post-myocarditis)

ARVC

Iron overload CMP

Takotsubo-CMP

LV non-compaction

LGE

RV 3 Ch “Inflow Outflow view”Triangle of dysplasia

(inflow, outflow, RV apex)

Right ventricle• RV dilatation• RVEF ↓• RV dyskinesia• Subtricuspid aneurysm

Left ventricle• Normal LV dimensions• Preserved LVEF• Normal regional wall

motion

SAX 4 Ch

Major Task Force CMR criteria

Regional RV akinesia or dyskinesia or dyssynchronous RV contractionand 1 of the following: RVEDVi ♂: ≥110 mL/m2 ♀: ≥100 mL/m2

or RV ejection fraction ≤40%

RV fibrofatty replacement (66% RV, 15% LV involvement)no longer part of task force CMR criteria but further

supporting the diagnosis

ARVC

Imaging alone not sufficient for definite diagnosis

Diagnosis based on multiple major and minor criteria:

histology, ECG, arrhythmias, family history

Not only a right-ventricular disease!

1. Classical ARVC

2. “biventricular” variant

3. Left-Dominant Arrhythmogenic CMP (LDAC) arrhythmias

with RBBB morphology (+ infero-lateral T wave inversion)

classical ARVC with LBBB morphology arrhythmia

DD: RV/LV volume ratio:

classical ARVC: ≥1.4; biventricular ca. 1:1; LDAC: <1

ARVC AC (Arrhythmogenic Cardiomyopathy)

Epsilon Wave

Biventricular/LV variant

Quadrangle of dysplasia

3. Tissue characterization with MRI for DD of the “dilated ventricle”

Dilated cardiomyopathy [NICM ICM]

Myocarditis (post-myocarditis)

ARVC

Iron overload CMP

Takotsubo-CMP

LV non-compaction

T2* mapping and iron overloadMortality of Thalassaemia major in the UK

T2* T2*

Heart and liver iron content

[ESC CMR pocket guide 2.0]

Blood

transfusion

Iron

chelation

Iron overload cardiomyopathy

Risk of developing heart failure • T2* <10 ms: high

• T2* 10-20 ms: intermediate

• T2* > 20 ms: low

Potentially reversible cause of heart failure under effective

therapy

Dilated phenotype majority of patients, impaired systolic

function

Restrictive phenotype non-dilated ventricles, preserved

systolic function, diastolic dysfunction, enlarged atria

T2* map

3. Tissue characterization with MRI for DD of the “dilated ventricle”

Dilated cardiomyopathy [NICM ICM]

Myocarditis (post-myocarditis)

ARVC

Iron overload CMP

Takotsubo CMP

LV non-compaction

The four different types of Takotsubo

Templin C et al. N Engl J Med. 2015

82%

15%

2%

1-2%

Basal

ballooning

„chestnut“

Apical

ballooning

Midventricular

ballooning

Transient systolic dysfunction with apical ballooning/akinesia and basal hyperkinesia.

CMR: typical Takotsubo pattern

4 Ch 3 Ch 2 Ch

No evidence of LGE or myocardial infarction.

Cin

eSSFP

T2 M

app

ing

LGE

Myocardial oedema in the areas of wall motion abnormality.

Tako-Tsubo!?

Systolic dysfunction with apical akinesia/dyskinesia and basal hyperkinesia.

Acute MI (type 2) mimicking Takotsubo.

4 Ch 3 Ch 2 Ch

Acute transmural MI with microvascular obstruction (prolonged vasospasm in apical LAD territory).

Cin

eSSFP

T2 M

app

ing

LGE

Myocardial oedema in the areas of wall motion abnormality.

MVO

3. Tissue characterization with MRI for DD of the “dilated ventricle”

Dilated cardiomyopathy [NICM ICM]

Myocarditis (post-myocarditis)

ARVC

Iron overload CMP

Takotsubo-CMP

LV non-compaction CMP

LV non-compaction CMP

Aetiology

a) incomplete compaction of spongy myocardium

LV Non-compaction cardiomyopathy (LVNC)

b) hypertrabeculation due to aberration of cardiogenesis

Excessive trabeculation cardiomyopathy (ET)

LV non-compaction CMP

Triad of Clinical Presentation

1. heart failure

2. thromboembolism

3. malignant arrhythmias/SCD

Normal pronounced trabeculation LVNC

LV non-compaction CMP

ESC CMR pocket guide 2.0

LV non-compaction CMP

ESC CMR pocket guide 2.0

In the context of intermediate pre-test probability!

Difficult diagnosis…

Patient with family history of

cardiomyopathy

• Marked trabeculation of all LV walls

except the interventricular septum

Most likely LV non-compaction CMP

Patient with no clinical features of

LVNC

• Marked LV trabeculation, primarily in

the lateral wall

• No other abnormalities

Most likely anatomical variant

A B

A B

ESC CMR pocket guide 2.0

Clinical algorithm

Nay Aung et al. JACC CV Imaging 2017

ICD?

OAC?

OMT?

LV non-compaction CMP

Conservative diagnosis

• (genetic) overlap with DCM, HCM, ARVC, IHD

Often over-diagnosed, particular in

• DCM (thin compacted myocardium)

• Afro-Americans

Excessive trabeculation + no other feature = benign

Current criteria may over-diagnose LV non-compaction.

New guidance is anticipated…

3. Tissue characterization with MRI for DD of the “thick ventricle”

c

Hypertrophic cardiomyopathy (HCM)

Amyloidosis

Anderson-Fabry

Athlete’s heart

(Hypertensive heart disease)

HCM

chordal SAM inferobasal crypts

hypokinesia ofhypertrophied segments

LGE of anteriorRV hinge point

Wall thickness (≥15 mm)?

SAM?

Crypts?

Hypokinesia of hypertrophy?

Fibrosis of hypertrophy?

Differential diagnoses

Hypertrophic CMP(1:500)

• 60%: asymmetric septal HCM

• 25-30%: symmetric concentric

HCM

• 10%: apical HCM (Yamaguchi)

apical obliteration of LV cavity

• midcavity HCM apical pouch

• 18%: RV hypertrophy

B

D

G

H

I

Why CMR in HCM?

2D Echo CMR

Non-diagnostic Apical HCM

18 mm 35 mm

SCD risk factor

Why CMR in HCM?

Precise assessment of wall thickness and extent/localisation of

hypertrophy

Detection and quantification of myocardial fibrosis ICD?

DD: Sarcomeric/familial HCM (sHCM) Phenocopies of HCM

HCM: #1 SCD in the young family screening

3. Tissue characterization with MRI for DD of the “thick ventricle”

Hypertrophic cardiomyopathy (HCM)

Amyloidosis

Anderson-Fabry

Athlete’s heart

(Hypertensive heart disease)

AL amyloidosis

Fabry disease

ATTR amyloidosis

sarcomeric HCM

EACVI CMR textbook 2018

Phenocopies of HCM

Mostly symmetrical and contiguous hypertrophy

Rare occurrence of LVOT obstruction

Typical pattern of LGE

Low native T1 value (Fabry fatty infiltration)

Phenocopies of HCM

Global

subendocardialPatchy

subendocardial

Amyloidosis Fabry

midwall

inferolateral

Tissue characterization

Normal native T1

map

„Fatty“ native T1

mapMidwall

Inferolateral LGE

Sado DM et al. Circ Cardiovasc Imaging 2013

Healthy Anderson-Fabry

Amyloidosis: Multi-modality imaging

Echo

- diastology

- AV stenosis

- strain

Tc-99m bone scan

- Perugini 2/3

ATTR

CMR

- ECV

- DD „thick

ventricle“

- (AL/ATTR)

(EMB)

- AL amyloidosis

- Subtypes, DD

Tissue characterization

Haaf P et al. JCMR 2016

ECV >>40% in

Amyloidosis

Normal ECV

nT1 in Fabry

ECV >30% in

HCM

3. Tissue characterization with MRI for DD of the “thick ventricle”

Hypertrophic cardiomyopathy (HCM)

Amyloidosis

Anderson-Fabry

Athlete’s heart

(Hypertensive heart disease)

Gray Zone (12-15 mm):Athlete’s Heart HCM

Athletes

True cellular hypertrophy

ECV↓

Hypertrophic CMP

Cellular disarray and extracellular matrix

expansion

ECV↑

Swoboda P. et al. JACC 2016

MRI & Cardiomyopathies

1. Definition of Cardiomyopathy

2. Ischemic vs Non-ischemic cardiomyopathy

3. Tissue characterization with MRI for differential diagnosis of the

a.“dilated ventricle”

b.“thick ventricle”

4. Decision making: MRI for arrhythmogenic risk stratification

4. Decision making: Arrhythmogenic risk

Would you rely on a decision making tool for ICD

implantation that misses 70-80% of future SCD?

70-80% of those who suffer SCD have an LVEF >35%!

Danish Trial: n=1116 NICM, EF<35%, no difference in

all-cause mortality (ICD vs. no ICD)

Furthermore, about 50% of all ICDs implanted are never

used (=potentially harmful: lead infection, inappropriate

shocks, atrial tachyarrhythmias…).

Adequacy of EF as (sole) gatekeeper to ICD?

Decision making:Arrhythmogenic risk

[Buxton AE, J Electrocardiol, 2016] [Stecker EC, JACC 2006] [Kober L, N Engl J Med, 2016]

Arrhythmogenic risk

[Disertori M, J Am Coll Cardiol Img, 2016] [Wu KC, Circ Cardiov Imag, 2017] [Klem I, JACC, 2012]

ICD discharge and SCD rates

Patients with preserved EF and

scarring on CMR have a similar

event rate to those with EF<30%

Patients with EF<30% but no scar

have a similar event rate to those

with preserved EF.

[Klem I, JACC, 2012]

Arrhythmogenic risk

Infarct/Scar Quantification

Meta-analysis (n=2.850, 3 y FU)

Infarct size >10% OR 5.6 [4.2-7.5]

[Disertori M, J Am Coll Cardiol Img, 2016] [Wu KC, Circ Cardiov Imag, 2017] [Klem I, JACC, 2012]

EF threshold to arbitrate ICD prescription:

lots of unused implants in pt’s with low EF

overlooked arrhythmic deaths in many patients with preserved EF

Outlook: Reliance on LVEF as the sole arbiter for ICD must end.

Better: LVEF + scar quantification for arrhythmogenic risk stratification.

Decision makingICD discharge and SCD rates

[Klem I, JACC, 2012]

Arrhythmogenic risk in HCM

HCM

Multi-parameter approach

Much better risk stratification

LGE & Arrhythmogenic/SCD Risk

Chan et al. Circulation 2014

7x

Arbitrator LGE in HCM

Maron BJ

JACC Cardiovasc Imag

2016

Summary: MRI & Cardiomyopathies

1. CMR: ideal imaging modality for tissue characterization and

cardiomyopathies

2. DCM: ICM vs NICM?

3. ARVC biventricular/LV forms AC

4. LVNC conservative diagnosis ET

5. HCM and its phenocopies

6. Amyloidosis multimodality imaging (Echo, CMR, bone scan)

7. Arrhythmogenic risk (ICD?)

a) DCM: LVEF LGE (No LGE vs. ≥10% LGE)

b) HCM: ESC risk calculator (No LGE vs. ≥15% LGE)

CMR pocket Guide

www.cmr-guide.com

Differential diagnosis in LV hypertrophy (I)

Differential diagnosis in LV hypertrophy (II)

CMR

Arbitrator

Maron BJ

JACC Cardiovasc Imag

2016

Added value of CMR vs. 2D Echo

• Optimal visualization of

– LV apex (apical HCM, LV thrombus)

– Lateral wall (circumflex territory)

– Basal septum (early asymmetricseptal HCM)

– RV (ARVC, right heart infarction, GUCH, cardiac shunts)